CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 123 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,930,894 | +39.9% | 129,504 | +2.8% | 0.00% | 0.0% |
| Q2 2023 | $1,379,984 | +336.7% | 126,026 | +24.0% | 0.00% | – |
| Q1 2022 | $316,000 | -11.5% | 101,595 | -3.9% | 0.00% | – |
| Q4 2021 | $357,000 | -8.0% | 105,702 | -0.5% | 0.00% | -100.0% |
| Q3 2021 | $388,000 | -14.5% | 106,187 | +2.0% | 0.00% | 0.0% |
| Q2 2021 | $454,000 | -14.2% | 104,101 | -10.6% | 0.00% | 0.0% |
| Q1 2021 | $529,000 | -24.4% | 116,461 | -4.5% | 0.00% | 0.0% |
| Q4 2020 | $700,000 | -9.9% | 121,941 | +13.6% | 0.00% | 0.0% |
| Q3 2020 | $777,000 | +83.3% | 107,360 | -11.7% | 0.00% | 0.0% |
| Q2 2020 | $424,000 | +236.5% | 121,525 | +43.2% | 0.00% | – |
| Q1 2020 | $126,000 | -24.1% | 84,887 | 0.0% | 0.00% | – |
| Q4 2019 | $166,000 | -61.8% | 84,887 | -0.1% | 0.00% | -100.0% |
| Q3 2019 | $435,000 | -29.0% | 85,005 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $613,000 | -40.7% | 85,580 | +9.9% | 0.00% | -50.0% |
| Q1 2019 | $1,034,000 | +68.7% | 77,843 | -0.1% | 0.00% | +100.0% |
| Q4 2018 | $613,000 | +4.6% | 77,946 | +47.4% | 0.00% | 0.0% |
| Q3 2018 | $586,000 | -21.0% | 52,889 | -4.3% | 0.00% | 0.0% |
| Q2 2018 | $742,000 | – | 55,261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |